Healthcare / BiotechnologyXETRA
$22.05
+1.30 (+6.10%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-44.1M · quality 69.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$390M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-16.2%
↓Gross Margin
8.0%
↓Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.5%
FCF CAGR
—
FCF margin
-99.2%
FCF / Net income
0.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $44.5M · net income $-64.7M · FCF $-44.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $44.5M | $44.5M | $69.7M | $77.7M | $42.5M |
| Net Income | $-64.7M | $-64.7M | $-125.7M | $75.8M | $36.0M |
| EBITDA | $-888000.00 | $-888000.00 | $-4.1M | $81.0M | $38.6M |
| EPS | — | — | -7.18 | 4.72 | 2.59 |
| Gross Margin | 8.0% | 8.0% | 21.3% | 30.0% | 28.4% |
| Operating Margin | -68.6% | -68.6% | -33.8% | -0.5% | -41.7% |
| Net Margin | -145.5% | -145.5% | -180.4% | 97.6% | 84.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.06 | 0.08 |
| Current Ratio | 2.33 | 2.33 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-44.1M | $-44.1M | $-53.2M | $-31.0M | $-45.6M |
| Returns | |||||
| ROE | -16.2% | -16.2% | -27.2% | 15.1% | 10.1% |
| Valuation | |||||
| P/E | — | — | — | 11.19 | 35.71 |
| EV/EBITDA | — | — | — | 10.49 | 33.79 |
| P/B | 0.98 | 0.98 | 2.07 | 1.69 | 3.60 |
| Growth & Yield | |||||
| Revenue Growth | -36.2% | -36.2% | -10.3% | 82.8% | — |
| EPS Growth | — | — | -252.1% | 82.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-5.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-7.18 → n/d
Residual
-5.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.